Physician profile
Robert M Kahn
NPI 1477577559
$356.70
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $124 · 2020: $189 · 2021: $43.97.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $75.26 | 2020-2021 | |
| Astellas Pharma US INC | $62.99 | 2020-2021 | |
| Avanir Pharmaceuticals, INC. | $36.76 | 2019-2020 | |
| Glaxosmithkline, LLC. | $36.35 | 2019-2020 | |
| Abbvie INC. | $33.50 | 2020 | |
| Amgen INC. | $24.55 | 2019 | |
| Alkermes, INC. | $23.99 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $23.24 | 2019 | |
| Lilly USA, LLC | $15.29 | 2019 | |
| Mdd US Operations, LLC | $13.23 | 2019 | |
| Merck Sharp & Dohme LLC | $11.54 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Kahn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.